Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Cash: 2010-2025

Historic Change in Cash for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $44.8 million.

  • Ani Pharmaceuticals' Change in Cash rose 147.13% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 344.75%. This contributed to the annual value of -$76.2 million for FY2024, which is 145.40% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Cash of $44.8 million as of Q3 2025, which was down 34.10% from $68.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Cash ranged from a high of $94.0 million in Q2 2023 and a low of -$95.1 million during Q3 2024.
  • Moreover, its 3-year median value for Change in Cash was $14.5 million (2023), whereas its average is $19.0 million.
  • In the last 5 years, Ani Pharmaceuticals' Change in Cash soared by 947.41% in 2021 and then plummeted by 1,567.69% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Change in Cash stood at $85.0 million in 2021, then slumped by 109.47% to -$8.1 million in 2022, then soared by 448.36% to $28.0 million in 2023, then crashed by 100.44% to -$123,000 in 2024, then soared by 147.13% to $44.8 million in 2025.
  • Its Change in Cash was $44.8 million in Q3 2025, compared to $68.0 million in Q2 2025 and $4.9 million in Q1 2025.